Preliminary results of validation of New Fundamental Assessment Scale for Clinical Symptoms in psychotic disorders (FACS-P)
Suggested citation:
Reznik AM, Zorkina YaA, Abramova OV, et al. [Preliminary results of validation of New Fundamental Assessment Scale for Clinical Symptoms in psychotic disorders (FACS-P)]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2022;(5):51-62. Russian
In this exploratory pilot study aimed at developing a New Fundamental Assessment Scale for Clinical Symptoms (FACS-P), which is based on fundamental knowledge about psychopathological symptoms, the validation of the FACS-P scale was carried out on 30 patients with schizophrenia against The Positive and Negative Syndrome Scale – PANSS, Clinical-Rated Dimensions of Psychotic Symptom Severity DSM-5 и Symptom Qualifier Scales ICD-11. Evaluation was performed in patients in an acute condition in hospital and 6 months later on outpatient treatment. Preliminary results of scale validation are presented, sufficient reliability (internal consistency and reproducibility), substantial and constructive validity as well as sensitivity of the new FACS-P scale were shown.
Keywords schizophrenia; FACS-P; PANSS; DSM-5; SQS ICD-11
1. Zorkina Y, Morozova A, Abramova O, et al. Sex differences in social functioning of patients with schizophrenia depending on the age of onset and severity of the disease. Early Interv Psychiatry. 2021;15(5):1197–209. DOI: https://doi.org/10.1111/eip.13063 2. Nucifora FC Jr, Woznica E, Lee BJ, et al. Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257. DOI: https://doi.org/10.1016/j.nbd.2018.08.016 3. Harrison PJ. Recent genetic findings in schizophrenia and their therapeutic relevance. J Psychopharmacol. 2015;29(2):85–96. DOI: https://doi.org/10.1177/0269881114553647 4. Davison J, O'Gorman A, Brennan L, et al. A systematic review of metabolite biomarkers of schizophrenia. Schizophr Res. 2018;195:32–50. DOI: https://doi.org/10.1016/j.schres.2017.09.021 5. Srivastava A, Dada O, Qian J, et al. Epigenetics of Schizophrenia. Psychiatry Res. 2021;305:114218. DOI: https://doi.org/10.1016/j.psychres.2021.114218 6. Tomasik J, Rahmoune H, Guest PC, et al. Neuroimmune biomarkers in schizophrenia. Schizophr Res. 2016;176(1):3–13. DOI: https://doi.org/10.1016/j.schres.2014.07.025 7. Mohammadi A, Rashidi E, Amooeian VG. Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. Psychiatry Res. 2018;265:25–38. DOI: https://doi.org/10.1016/j.psychres.2018.04.036 8. He K, Guo C, He L, et al. MiRNAs of peripheral blood as the biomarker of schizophrenia. Hereditas. 2017;155:9. DOI: https://doi.org/.1186/s41065-017-0044-2 9. Morozova AY, Zubkov EA, Zorkina YA, et al. [Genetic aspects of schizophrenia]. Zh Nevrol Psikhiatr Im SS Korsakova. 2017;117(6):126–32. (In Russ.) DOI: https://doi.org/10.17116/jnevro201711761126-132 10. Messamore E. The niacin response biomarker as a schizophrenia endophenotype: A status update. Prostaglandins Leukot Essent Fatty Acids. 2018;136:95–7. DOI: https://doi.org/10.1016/j.plefa.2017.06.014 11. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7. DOI: https://doi.org/10.1038/nature13595 12. Liu J, Li S, Li X, et al. Genome-wide association study followed by trans-ancestry meta-analysis identify 17 new risk loci for schizophrenia. BMC Med. 2021;19(1):177. DOI: https://doi.org/10.1186/s12916-021-02039-9 13. Kolesnichenko EV, Barylnik JuB, Borodulin VB, et al. Issledovanie geneticheskogo polimorfizma pri paranoidnoj shizofrenii v saratovskoj oblasti. Fundamental'nye issledovanija. 2013;11(1):62–5. (In Russ.) 14. Kolesnichenko EV, Barylnik YB, Golimbet VE. [Influence of BDNF gene on phenotypic expression of paranoid schizophrenia]. Social and clinical psychiatry. 2015;25(2):45–9. (In Russ.) 15. Hagemeyer N, Goebbels S, Papiol S, et al. A myelin gene causative of a catatonia-depression syndrome upon aging. EMBO Mol Med. 2012;4(6):528–39. DOI: https://doi.org/10.1002/emmm.201200230 16. Zhai J, Yu Q, Chen M, et al. Association of the brain-derived neurotrophic factor gene G196A rs6265 polymorphisms and the cognitive function and clinical symptoms of schizophrenia. Int J Clin Exp Pathol. 2013;6(8):1617–23. PMID: 23923080; PMCID: PMC3726978 17. McCullumsmith RE, Hammond JH, Shan D, et al. Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacology. 2014;39(1):65–87. DOI: https://doi.org/10.1038/npp.2013.239 18. Peng X, Bader JS, Avramopoulos D. Schizophrenia risk alleles often affect the expression of many genes and each gene may have a different effect on the risk: A mediation analysis. Am J Med Genet B Neuropsychiatr Genet. 2021;186(4):251–8. DOI: https://doi.org/10.1002/ajmg.b.32841 19. Kane JM. Tools to assess negative symptoms in schizophrenia. J Clin Psychiatry. 2013;74(6):e12. DOI: https://doi.org/10.4088/JCP.12045tx2c 20. Papadopulos TF. Ostrye jendogennye psihozy: psihopatologija i sistematika. Medicina. Moscow; 1975. 192 p. (In Russ.) 21. Morozov PV. Sindrom Kandinskogo–Klerambo: klinicheskie osobennosti i istorija voprosa. Psihiatrija. 2012;01–03(53–55):13–9. (In Russ.) 22. Smulevich AB, Klyushnik TP, Borisova PO, et al. [Catatonia (Actual Problems of Psychopatology and Clinical Systematics)]. Psikhiatriya. 2022;20(1):6–16. (In Russ.) DOI: https://doi.org/10.30629/2618-6667-2022-20-1-6-16 23. Borisova PO. [Nosological Dilemma and Clinical Polymorphism of the Catatonia Phenomenon]. Psikhiatriya. 2020;18(2):61–70. (In Russ.) DOI: https://doi.org/10.30629/2618-6667-2020-18-2-61-70 24. Panteleeva GP, Cucul'kovskaja MJa, Beljaev BS. Geboidnaja shizofrenija. Moscow: Medicina; 1986. 192 p. (In Russ.) 25. Ivanov MV, Neznanov NG. Negativnye i kognitivnye rasstrojstva pri jendogennyh psihozah: diagnostika, klinika, terapija. Saint-Petersburg: Izd. NIPNI im. V.M. Behtereva; 2008. 288 p. (In Russ.) 26. Blejher VM. Rasstrojstva myshlenija. Kiev: Zdorov’ja; 1983. 192 p. (In Russ.) 27. Kritskaja VP, Meleshko TK, Poljakov JuF. Patologija psihicheskoj dejatel'nosti pri shizofrenii: motivacija, obshhenie, poznanie. Moscow: Izd-vo MGU; 1991. 256 p. (In Russ.) 28. Dubnickaja JeB. Nebredovaja ipohondrija pri pogranichnyh sostojanijah (somatoformnye rasstrojstva) i vjalotekushhej shizofrenii (kliniko-geneticheskie aspekty). In: AB Smulevich, editor. Ipohondrija i somatoformnye rasstrojstva. Moscow; 1992. р. 17–39. (In Russ.) 29. Smulevich AB. Maloprogredientnaja shizofrenija i pogranichnye sostojanija. 2-e izd. Moscow: MEDpress-inform; 2009. 256 p. (In Russ.) 30. Efremova MD. K probleme sootnoshenija obsessivnyh i bredovyh projavlenij u bol'nyh shizofreniej (na modeli mizofobii). In: AB Smulevich, editor. Trevoga i obsessii. Moscow; 1998. p. 132–43. (In Russ.) 31. Smulevich AB, Vorob'ev VJu. Depersonalizacija (kliniko-psihopatologicheskie aspekty). Zh Nevrol Psikhiatr Im SS Korsakova. 1973;73(8):1242–52. (In Russ.) 32. Pyatnitskiy NYu. [Phenomenon of Depersonalization: the Term of H.-F. Amiel in the Concepts of L. Dugas and P. Janet]. Psikhiatriya. 2022;20(1):129–38. (In Russ.) DOI: https://doi.org/10.30629/2618-6667-2022-20-1-129-138 33. Ivanova E, Khan A, Liharska L, et al. Validation of the Russian Version of the Positive and Negative Syndrome Scale (PANSS-Ru) and Normative Data. Innov Clin Neurosci. 2018;15(9–10):32–48. 34. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fifth edition, DSM-5. 2013. 947 p. 35. Reed GM, First MB, Kogan CS, et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry. 2019;18(1):3–19. DOI: https://doi.org/10.1002/wps.20611 36. Gaebel W. Status of psychotic disorders in ICD-11. Schizophr Bull. 2012;38(5):895–8. DOI: https://doi.org/10.1093/schbul/sbs104 37. Keeley JW, Gaebel W. Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11. Epidemiol Psychiatr Sci. 2018;27(3):219–24. DOI: https://doi.org/10.1017/S2045796017000270 38. Kulygina M. New ICD-11 Diagnostic Guidelines for Mental Disorders: Challenging Implications for Psychology and Psychologists. Psychol Psychology Res Int J. 2019;4(6):000234. 39. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538–46. DOI: https://doi.org/10.4088/jcp.v58n1205 40. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334. DOI: https://doi.org/10.1007/BF02310555 41. Heilbronner U, Samara M, Leucht S, et al. The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects. Harv Rev Psychiatry. 2016;24(2):118–28. DOI: https://doi.org/10.1097/HRP.0000000000000092
DOI: http://dx.doi.org/10.47877/1560-957Х-2022-10505
Article Metrics
Metrics powered by PLOS ALM